K Pharma,Inc.
4896.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.21 | -0.20 | 0.00 |
| FCF Yield | -13.85% | 5.32% | -4.45% | -1.79% |
| EV / EBITDA | -5.85 | 13.90 | -19.20 | -48.39 |
| Quality | ||||
| ROIC | -36.63% | 10.09% | -26.51% | -120.13% |
| Gross Margin | 0.00% | 91.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.17 | 1.51 | 0.93 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | -324.51% | 213.01% | -100.41% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.69 | -8.92 | 3.42 | 0.85 |
| Interest Coverage | 0.00 | 30.89 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 8.34 | 0.00 | 0.69 |
| Cash Conversion Cycle | 0.00 | -4.06 | 0.00 | 392.04 |